Molecular determinants of resistance to antiandrogen therapy

Nature Medicine

Volumn 10, Issue 1, 2004, Pages 33-39

  Chen, Charlie D ^a   Welsbie, Derek S ^a   Tran, Chris ^a   Baek, Sung Hee ^a,b   Chen, Randy ^a   Vessella, Robert ^c   Rosenfeld, Michael G ^a,b   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; MESSENGER RNA; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MODEL; CONTROLLED STUDY; DNA MICROARRAY; GENE TARGETING; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; XENOGRAFT; DISEASE COURSE; DRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALIA;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; DISEASE PROGRESSION; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 1842612441     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm972     Document Type: Article

References (49)

1. Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001).
2. Gelmann, E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001-3015 (2002).
3. Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-138 (2002).
4. Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 2511-2515 (1999).
5. Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 21, 2673-2678 (2003).
6. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406 (1995).
7. Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995).
8. Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540 (1990).
9. Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J. Med. Chem. 45, 1439-1446 (2002).
10. Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285 (1999).
11. Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277, 29304-29314 (2002).
12. Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494 (1995).
13. Font de Mora, J. & Brown, M. AlB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20, 5041-5047 (2000).
14. Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell 3, 513-519 (1999).
15. Gregory, C.W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315-4319 (2001).
16. Li, P. et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am. J. Pathol. 161, 1467-1474 (2002).
17. Glass, C.K. & Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121-141 (2000).
18. Raffo, A.J. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55, 4438-4445 (1995).
19. McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940-6944 (1992).
20. Kinoshita, H. et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60, 3623-3630 (2000).
21. Shang, Y., Myers, M. & Brown, M. Formation of the androgen receptor transcription complex. Mol. Cell 9, 601-610 (2002).
22. Zhau, H.Y. et al. Androgen-repressed phenotype in human prostate cancer. Proc. Natl. Acad. Sci. USA 93, 15152-15157 (1996).
23. Wainstein, M.A. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 54, 6049-6052 (1994).
24. Ellis, W.J. et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin. Cancer Res. 2, 1039-1048 (1996).
25. Horoszewicz, J.S. et al. LNCaP model of human prostatic carcinoma. Cancer Res. 43, 1809-1818 (1983).
26. Klein, K.A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 3, 402-408 (1997).
27. Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
28. Gregory, C.W., Johnson, R.T., Jr., Mohler, J.L., French, F.S. & Wilson, E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898 (2001).
29. Huang, Z.Q., Li, J. & Wong, J. AR possesses an intrinsic hormone-independent transcriptional activity. Mol. Endocrinol. 16, 924-937 (2002).
30. Matias, P.M. et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275, 26164-26171 (2000).
31. Lobaccaro, J.M. et al. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. Mol. Cell. Endocrinol. 116, 137-147 (1996).
32. Migliaccio, A. et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J. 19, 5406-5417 (2000).
33. Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730 (2001).
34. Manolagas, S.C., Kousteni, S. & Jilka, R.L. Sex steroids and bone. Recent Prog. Horm. Res. 57, 385-409 (2002).
35. DePrimo, S.E. et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 3, RESEARCH0032 (2002).
36. Masiello, D., Cheng, S., Bubley, G.J., Lu, M.L. & Balk, S.P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277, 26321-26326 (2002).
37. Edwards, J., Krishna, N.S., Grigor, K.M. & Bartlett, J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89, 552-556 (2003).
38. Lattinen, S., Karhu, R., Sawyers, C.L., Vessella, R.L. & Visakorpi, T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer 35, 66-73 (2002).
39. Grad, J.M., Dai, J.L., Wu, S. & Burnstein, K.L. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol. Endocrinol. 13, 1896-1911 (1999).
40. Craft, N. et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59, 5030-5036 (1999).
41. Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238 (2003).
42. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003).
43. Shiau, A.K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
44. Norris, J.D. et al. Peptide antagonists of the human estrogen receptor. Science 285, 744-746 (1999).
45. Baek, S.H. et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-κB and β-amyloid precursor protein. Cell 110, 55-67 (2002).
46. Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002).
47. Schellhammer, P.F. et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J. Urol. 157, 1731-1735 (1997).
48. Sack, J.S. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. USA 98, 4904-4909 (2001).
49. Zhou, Z.X., Sar, M., Simental, J.A., Lane, M.V. & Wilson, E.M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J. Biol. Chem. 269, 13115-13123 (1994).